Managing HR+ HER2- Breast Cancer
Advances in genetic testing have created new possibilities for understanding the genetic and molecular composition of breast cancer tumors, and assessing what kinds of treatment plans will be best for specific individuals. CDK4/6 inhibitors and other new treatments have also improved the prognosis for early stage and late stage patients with hormone receptor-positive, HER2-negative breast cancer.
- Many breast cancer journeys start with testing to analyze the genetic and molecular makeup of the cancer. With the help of genetic testing, doctors can make better-informed decisions about how to approach treatment for the genetic makeup of your tumor.
- The Oncotype DX test is one genetic test that analyzes the tumors of people with early-stage HR+, HER2- breast cancer. The test can help predict the risk of your breast cancer returning.
- This test can also provide insight into whether a patient will benefit from chemotherapy.
The Importance of Genetic Sequencing
- Many breast cancer journeys start with testing to analyze the genetic and molecular makeup of the cancer. With the help of genetic testing, doctors can make better-informed decisions about how to approach treatment for the genetic makeup of your tumor.
- The Oncotype DX test is one genetic test that analyzes the tumors of people with early-stage HR+, HER2- breast cancer. The test can help predict the risk of your breast cancer returning.
- This test can also provide insight into whether a patient will benefit from chemotherapy.
- CDK4/6 inhibitors are a newer class of drugs given in conjunction with hormonal therapy for patients with HR+, HER2- breast cancer.
- These targeted therapies attack proteins known as the cyclin-dependent kinases 4 and 6 (CDK4/CDK6). These proteins control how quickly cells divide and multiply, and for women with breast cancer, these proteins can cause cancer cells to grow uncontrollably.
- CDK4/6 inhibitors like Verzenio have recently been shown to significantly cut the risk of recurrence in women with high risk early stage breast cancer.
Early Stage Treatment
- CDK4/6 inhibitors are a newer class of drugs given in conjunction with hormonal therapy for patients with HR+, HER2- breast cancer.
- These targeted therapies attack proteins known as the cyclin-dependent kinases 4 and 6 (CDK4/CDK6). These proteins control how quickly cells divide and multiply, and for women with breast cancer, these proteins can cause cancer cells to grow uncontrollably.
- CDK4/6 inhibitors like Verzenio have recently been shown to significantly cut the risk of recurrence in women with high risk early stage breast cancer.
- Clinical trials have yielded promising results for new possibilities of expanding life with metastatic, HR+, HER2-negative breast cancer.
- One such finding is that combining the CDK4/6 inhibitors with traditional hormonal therapy doubled the amount of time women could live without their breast cancer getting worse.
- CDK4/6 inhibitors have been show to improve overall survival in postmenopausal women with metastatic breast cancer.
Later Stage Treatment
- Clinical trials have yielded promising results for new possibilities of expanding life with metastatic, HR+, HER2-negative breast cancer.
- One such finding is that combining the CDK4/6 inhibitors with traditional hormonal therapy doubled the amount of time women could live without their breast cancer getting worse.
- CDK4/6 inhibitors have been show to improve overall survival in postmenopausal women with metastatic breast cancer.